In addition, it has been proposed that the reduced sensitivity and drug resistance to KIT inhibitors partially result from the hyperactivation of MAPK caused by the loss of SPRED1 – a model verified in human melanoma cell lines and in vivo zebrafish model (6, 101), but presently untested in mouse models and patient samples. This evidence concerns the gene KIT and melanoma.